Cocrystal Pharma Inc (nasdaq:COCP) Share Price

Company Profile

Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Contact
19805 North Creek Parkway
BothellWA98011
USA
T: +1 877 262-7123
E: [email protected]
https://www.cocrystalpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,735.93	75.33	-0.96%
DAX 40	25,085.30	286.45	-1.13%
Dow JONES (US)	52,326.31	541.67	-1.02%
FTSE 100	10,654.39	70.64	-0.66%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,912.60	96.26	-0.37%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,624.78	38.65	-0.50%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%